Dosing & Uses

Adult

Dosage Forms & Strengths

injectable solution, prefilled pen

• 250 mcg/mL (1.2 mL vial)
  
• 250 mcg/mL (2.4 mL vial)
  

Diabetes Mellitus, Type 2

Adjunct to diet and exercise to improve glycemic control with DM type 2; monotherapy or as an adjunct therapy with thiazolidinediones, metformin, or a sulfonylurea; or add-on therapy to insulin glargine (a long-acting insulin), with or without metformin and/or a thiazolidinedione, in patients who are not achieving adequate glycemic control on insulin glargine alone

Immediate-release (Byetta): 5 mcg SC q12hr within 60 minutes prior to meal intially; after 1 month, may increased to 10 mcg q12hr

Switching from immediate-release to extended-release

• Initiate weekly extended-release SC injections 1 day after discontinuing immediate-release exenatide (Byetta)
  
• May experience increased blood glucose levels for approximately 2 weeks after initiating extended-release (Bydureon) therapy
  
• May initiate extended-release exenatide without pretreating with the immediate-release dosage form
  

Dosage Modifications

Renal impairment

• Mild (CrCl 50-80 mL/min): No dosage adjustment required
  
• Moderate (CrCl 30-50 mL/min): Caution when initiating or escalating dose
  
• Severe (CrCl <30 mL/min) or ESRD: Not recommended
  
• Renal transplantation: Use with caution
  

Intracranial Hypertension (Orphan)

Orphan designation for idiopathic intracranial hypertension

Sponsor

• Alan Boyd Consultants Ltd; Electra House, Crewe Business Park; Crewe, UK
  

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Byetta 5 mcg only for the indication prescribed.